Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research.

Vesterinen T, Salmenkivi K, Mustonen H, Kuopio T, Lappi-Blanco E, Paavonen T, Vainio P, Knuuttila A, Carpén O, Haglund C, Arola J.

Virchows Arch. 2019 Aug 5. doi: 10.1007/s00428-019-02625-6. [Epub ahead of print]

PMID:
31385069
2.

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers.

Talwelkar SS, Nagaraj AS, Devlin JR, Hemmes A, Potdar S, Kiss EA, Saharinen P, Salmenkivi K, Mäyränpää MI, Wennerberg K, Verschuren EW.

Mol Cancer Ther. 2019 Oct;18(10):1863-1874. doi: 10.1158/1535-7163.MCT-18-0573. Epub 2019 Jul 18.

PMID:
31320402
3.

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.

Vesterinen T, Kuopio T, Ahtiainen M, Knuuttila A, Mustonen H, Salmenkivi K, Arola J, Haglund C.

Endocr Connect. 2019 Aug 1;8(8):1168-1175. doi: 10.1530/EC-19-0308.

4.

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.

Kettunen E, Savukoski S, Salmenkivi K, Böhling T, Vanhala E, Kuosma E, Anttila S, Wolff H.

BMC Cancer. 2019 May 28;19(1):507. doi: 10.1186/s12885-019-5652-y.

5.

Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors.

Vesterinen T, Leijon H, Mustonen H, Remes S, Knuuttila A, Salmenkivi K, Vainio P, Arola J, Haglund C.

J Clin Endocrinol Metab. 2019 Jun 1;104(6):2083-2093. doi: 10.1210/jc.2018-01931.

PMID:
30657933
6.

Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor.

Vesterinen T, Mononen S, Salmenkivi K, Mustonen H, Räsänen J, Salo JA, Ilonen I, Knuuttila A, Haglund C, Arola J.

Acta Oncol. 2018 Aug;57(8):1109-1116. doi: 10.1080/0284186X.2018.1441543. Epub 2018 Feb 20. Erratum in: Acta Oncol. 2019 May;58(5):819. Räsänen J [added], Salo JA [added].

PMID:
29463166
7.

Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.

Närhi K, Nagaraj AS, Parri E, Turkki R, van Duijn PW, Hemmes A, Lahtela J, Uotinen V, Mäyränpää MI, Salmenkivi K, Räsänen J, Linder N, Trapman J, Rannikko A, Kallioniemi O, Af Hällström TM, Lundin J, Sommergruber W, Anders S, Verschuren EW.

J Pathol. 2018 May;245(1):101-113. doi: 10.1002/path.5059. Epub 2018 Apr 2. Erratum in: J Pathol. 2019 Jan;247(1):147.

8.

Analysis of the Histologic Features Associated With Interobserver Variation in Idiopathic Pulmonary Fibrosis.

Mäkelä K, Hodgson U, Piilonen A, Kelloniemi K, Bloigu R, Sutinen E, Salmenkivi K, Rönty M, Lappi-Blanco E, Myllärniemi M, Kaarteenaho R.

Am J Surg Pathol. 2018 May;42(5):672-678. doi: 10.1097/PAS.0000000000001031.

PMID:
29438171
9.

Asbestos-associated genome-wide DNA methylation changes in lung cancer.

Kettunen E, Hernandez-Vargas H, Cros MP, Durand G, Le Calvez-Kelm F, Stuopelyte K, Jarmalaite S, Salmenkivi K, Anttila S, Wolff H, Herceg Z, Husgafvel-Pursiainen K.

Int J Cancer. 2017 Nov 15;141(10):2014-2029. doi: 10.1002/ijc.30897. Epub 2017 Aug 2.

10.

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.

Nagaraj AS, Lahtela J, Hemmes A, Pellinen T, Blom S, Devlin JR, Salmenkivi K, Kallioniemi O, Mäyränpää MI, Närhi K, Verschuren EW.

Cell Rep. 2017 Jan 17;18(3):673-684. doi: 10.1016/j.celrep.2016.12.059.

11.

Incidence, Risk Factors, and Outcome of Life-Threatening Ventricular Arrhythmias in Giant Cell Myocarditis.

Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M.

Circ Arrhythm Electrophysiol. 2016 Dec;9(12). pii: e004559.

PMID:
27913400
12.

Long-term outcome and its predictors in giant cell myocarditis.

Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M.

Eur J Heart Fail. 2016 Dec;18(12):1452-1458. doi: 10.1002/ejhf.606. Epub 2016 Jul 13.

13.

HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.

Leijon H, Salmenkivi K, Heiskanen I, Hagström J, Louhimo J, Heikkilä P, Ristimäki A, Paavonen T, Metso S, Mäenpää H, Haglund C, Arola J.

APMIS. 2016 Sep;124(9):757-63. doi: 10.1111/apm.12571. Epub 2016 Jun 30.

PMID:
27357268
14.

[Molecular pathologic diagnosis of lung cancer requires basic knowledge also from clinicians].

Lappi-Blanco E, Salmenkivi K, Kytölä S, Kononen J.

Duodecim. 2016;132(6):593-9. Review. Finnish.

PMID:
27132299
15.

[Diagnostics of non-small cell lung carcinoma].

Salmenkivi K, Knuuttila A.

Duodecim. 2014;130(7):701-4. Review. Finnish.

PMID:
24772787
16.

Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods.

Tuononen K, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K, Knuuttila A, Remes S, Telaranta-Keerie AI, Bloor S, Ellonen P, Knuutila S.

Biomed Res Int. 2013;2013:757490. doi: 10.1155/2013/757490. Epub 2013 Jan 20.

17.

Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.

Tuononen K, Mäki-Nevala S, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K, Andrews JM, Telaranta-Keerie AI, Hannula S, Lagström S, Ellonen P, Knuuttila A, Knuutila S.

Genes Chromosomes Cancer. 2013 May;52(5):503-11. doi: 10.1002/gcc.22047. Epub 2013 Jan 30.

PMID:
23362162
18.

Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.

Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M.

Circ Heart Fail. 2013 Jan;6(1):15-22. doi: 10.1161/CIRCHEARTFAILURE.112.969261. Epub 2012 Nov 13.

PMID:
23149495
19.

Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.

Kivelä AJ, Knuuttila A, Räsänen J, Sihvo E, Salmenkivi K, Saarnio J, Pastorekova S, Pastorek J, Waheed A, Sly WS, Salo JA, Parkkila S.

Bioorg Med Chem. 2013 Mar 15;21(6):1483-8. doi: 10.1016/j.bmc.2012.09.018. Epub 2012 Sep 18.

PMID:
23036334
20.

Expression of snail, twist, and Zeb1 in malignant mesothelioma.

Merikallio H, Pääkkö P, Salmenkivi K, Kinnula V, Harju T, Soini Y.

APMIS. 2013 Jan;121(1):1-10. doi: 10.1111/j.1600-0463.2012.02931.x. Epub 2012 Jun 26.

PMID:
23030626
21.

Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.

Nymark P, Aavikko M, Mäkilä J, Ruosaari S, Hienonen-Kempas T, Wikman H, Salmenkivi K, Pirinen R, Karjalainen A, Vanhala E, Kuosma E, Anttila S, Kettunen E.

Mol Oncol. 2013 Feb;7(1):29-40. doi: 10.1016/j.molonc.2012.07.006. Epub 2012 Aug 7.

22.

Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung.

Leppäranta O, Sens C, Salmenkivi K, Kinnula VL, Keski-Oja J, Myllärniemi M, Koli K.

Cell Tissue Res. 2012 Jun;348(3):491-503. doi: 10.1007/s00441-012-1385-9. Epub 2012 Mar 22.

PMID:
22434388
23.

Outcome of patients with ductal carcinoma in situ and sentinel node biopsy.

Meretoja TJ, Heikkilä PS, Salmenkivi K, Leidenius MH.

Ann Surg Oncol. 2012 Jul;19(7):2345-51. doi: 10.1245/s10434-012-2287-5. Epub 2012 Mar 7.

PMID:
22395995
24.

Cysteine-rich protein 1 is regulated by transforming growth factor-β1 and expressed in lung fibrosis.

Järvinen PM, Myllärniemi M, Liu H, Moore HM, Leppäranta O, Salmenkivi K, Koli K, Latonen L, Band AM, Laiho M.

J Cell Physiol. 2012 Jun;227(6):2605-12. doi: 10.1002/jcp.23000.

PMID:
21882188
25.

Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy.

Sevastianova K, Sutinen J, Greco D, Sievers M, Salmenkivi K, Perttilä J, Olkkonen VM, Wågsäter D, Lidell ME, Enerbäck S, Eriksson P, Walker UA, Auvinen P, Ristola M, Yki-Järvinen H.

Diabetes. 2011 Jul;60(7):1894-900. doi: 10.2337/db11-0075. Epub 2011 May 20.

26.

Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer.

Nymark P, Guled M, Borze I, Faisal A, Lahti L, Salmenkivi K, Kettunen E, Anttila S, Knuutila S.

Genes Chromosomes Cancer. 2011 Aug;50(8):585-97. doi: 10.1002/gcc.20880. Epub 2011 May 11.

PMID:
21563230
27.

Diagnosing isolated cardiac sarcoidosis.

Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivistö SM, Kupari M.

J Intern Med. 2011 Nov;270(5):461-8. doi: 10.1111/j.1365-2796.2011.02396.x. Epub 2011 Jun 1.

28.

Role of RNA binding protein HuR in ductal carcinoma in situ of the breast.

Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilén ST, Laakso M, Leidenius M, Salo T, Hautaniemi S, Gorospe M, Heikkilä P, Haglund C, Ristimäki A.

J Pathol. 2011 Aug;224(4):529-39. doi: 10.1002/path.2889. Epub 2011 Apr 11.

29.

A novel screening method detects herpesviral DNA in the idiopathic pulmonary fibrosis lung.

Pulkkinen V, Salmenkivi K, Kinnula VL, Sutinen E, Halme M, Hodgson U, Lehto J, Jääskeläinen A, Piiparinen H, Kere J, Lautenschlager I, Lappalainen M, Myllärniemi M.

Ann Med. 2012 Mar;44(2):178-86. doi: 10.3109/07853890.2010.532151. Epub 2011 Jan 24.

PMID:
21254895
30.

Control of early Aspergillus mortality after lung transplantation: outcome and risk factors.

Eriksson M, Lemström K, Suojaranta-Ylinen R, Martelius T, Harjula A, Sipponen J, Halme M, Piilonen A, Salmenkivi K, Anttila VJ, Hämmäinen P.

Transplant Proc. 2010 Dec;42(10):4459-64. doi: 10.1016/j.transproceed.2010.09.116.

PMID:
21168718
31.

Proteomic studies on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

Ohlmeier S, Mazur W, Salmenkivi K, Myllärniemi M, Bergmann U, Kinnula VL.

Proteomics Clin Appl. 2010 Jan;4(1):97-105. doi: 10.1002/prca.200900128. Epub 2010 Jan 7.

PMID:
21137019
32.

Variability in the precursor proteins of collagen I and III in different stages of COPD.

Harju T, Kinnula VL, Pääkkö P, Salmenkivi K, Risteli J, Kaarteenaho R.

Respir Res. 2010 Nov 30;11:165. doi: 10.1186/1465-9921-11-165.

33.

Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma.

Vehviläinen P, Koli K, Myllärniemi M, Lindholm P, Soini Y, Salmenkivi K, Kinnula VL, Keski-Oja J.

Hum Pathol. 2011 Feb;42(2):269-78. doi: 10.1016/j.humpath.2010.07.005. Epub 2010 Nov 24.

PMID:
21106222
34.

Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD.

Ishikawa N, Ohlmeier S, Salmenkivi K, Myllärniemi M, Rahman I, Mazur W, Kinnula VL.

Respir Res. 2010 Sep 13;11:123. doi: 10.1186/1465-9921-11-123.

35.

Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Mazur W, Lindholm P, Vuorinen K, Myllärniemi M, Salmenkivi K, Kinnula VL.

APMIS. 2010 Sep 1;118(9):703-12. doi: 10.1111/j.1600-0463.2010.02646.x.

PMID:
20718723
36.

[Cardiac sarcoidosis].

Kandolin R, Lehtonen J, Schildt J, Granér M, Salmenkivi K, Ahonen A, Karhumäki L, Kupari M.

Duodecim. 2009;125(21):2344-50. Finnish.

PMID:
19999658
37.

The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.

Sjöström-Mattson J, Von Boguslawski K, Bengtsson NO, Mjaaland I, Salmenkivi K, Blomqvist C.

Acta Oncol. 2009;48(8):1137-43. doi: 10.3109/02841860902988688.

PMID:
19863221
38.

Reduced phosphorylation of the TGF-Beta signal transducer Smad2 in emphysematous human lung.

Leppäranta O, Myllärniemi M, Salmenkivi K, Kinnula VL, Keski-Oja J, Koli K.

COPD. 2009 Aug;6(4):234-41.

PMID:
19811381
39.

High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma.

Häyry V, Salmenkivi K, Arola J, Heikkilä P, Haglund C, Sariola H.

Endocr Relat Cancer. 2009 Dec;16(4):1211-8. doi: 10.1677/ERC-09-0049. Epub 2009 Jul 29.

PMID:
19641025
40.

Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis.

Leppäranta O, Pulkkinen V, Koli K, Vähätalo R, Salmenkivi K, Kinnula VL, Heikinheimo M, Myllärniemi M.

Am J Respir Cell Mol Biol. 2010 May;42(5):626-32. doi: 10.1165/rcmb.2009-0021OC. Epub 2009 Jul 13.

PMID:
19597127
41.

CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.

Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S.

Genes Chromosomes Cancer. 2009 Jul;48(7):615-23. doi: 10.1002/gcc.20669.

PMID:
19396864
42.

Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease.

Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllärniemi M, Kinnula VL.

J Proteome Res. 2008 Dec;7(12):5125-32. doi: 10.1021/pr800423x.

PMID:
19367700
43.

DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure.

Kettunen E, Aavikko M, Nymark P, Ruosaari S, Wikman H, Vanhala E, Salmenkivi K, Pirinen R, Karjalainen A, Kuosma E, Anttila S.

Br J Cancer. 2009 Apr 21;100(8):1336-42. doi: 10.1038/sj.bjc.6605012. Epub 2009 Mar 31.

44.

Oxidative stress in non-small cell lung cancer: role of nicotinamide adenine dinucleotide phosphate oxidase and glutathione.

Ilonen IK, Räsänen JV, Sihvo EI, Knuuttila A, Salmenkivi KM, Ahotupa MO, Kinnula VL, Salo JA.

Acta Oncol. 2009;48(7):1054-61. doi: 10.1080/02841860902824909.

PMID:
19308756
45.

Molecular alterations at 9q33.1 and polyploidy in asbestos-related lung cancer.

Nymark P, Kettunen E, Aavikko M, Ruosaari S, Kuosma E, Vanhala E, Salmenkivi K, Pirinen R, Karjalainen A, Knuutila S, Wikman H, Anttila S.

Clin Cancer Res. 2009 Jan 15;15(2):468-75. doi: 10.1158/1078-0432.CCR-08-1852.

46.

Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.

Lindholm PM, Soini Y, Myllärniemi M, Knuutila S, Heikinheimo M, Kinnula VL, Salmenkivi K.

J Clin Pathol. 2009 Apr;62(4):339-44. doi: 10.1136/jcp.2008.060533. Epub 2008 Dec 5.

PMID:
19060016
47.

Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis.

Vuorinen K, Ohlmeier S, Leppäranta O, Salmenkivi K, Myllärniemi M, Kinnula VL.

J Histochem Cytochem. 2008 Oct;56(10):951-9. doi: 10.1369/jhc.2008.951806. Epub 2008 Jul 7.

48.

The prevalence of and risk factors for four or more metastatic axillary lymph nodes in breast cancer patients undergoing sentinel node biopsy.

Leidenius M, Vaalavirta L, Heikkilä P, von Smitten K, Salmenkivi K.

J Surg Oncol. 2008 Jul 1;98(1):21-6. doi: 10.1002/jso.21085.

PMID:
18484087
49.

Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH.

Lindholm PM, Salmenkivi K, Vauhkonen H, Nicholson AG, Anttila S, Kinnula VL, Knuutila S.

Cytogenet Genome Res. 2007;119(1-2):46-52. Epub 2007 Dec 14.

PMID:
18160781
50.

Gremlin localization and expression levels partially differentiate idiopathic interstitial pneumonia severity and subtype.

Myllärniemi M, Vuorinen K, Pulkkinen V, Kankaanranta H, Aine T, Salmenkivi K, Keski-Oja J, Koli K, Kinnula V.

J Pathol. 2008 Mar;214(4):456-63.

PMID:
18072275

Supplemental Content

Loading ...
Support Center